BioLineRx (NASDAQ:BLRX) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note released on Friday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of BioLineRx in a research note on Wednesday.

BioLineRx Stock Down 1.5 %

BioLineRx stock traded down $0.01 during midday trading on Friday, reaching $0.44. The stock had a trading volume of 225,865 shares, compared to its average volume of 347,987. BioLineRx has a 1-year low of $0.39 and a 1-year high of $1.93. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.49 and a current ratio of 1.61. The firm’s fifty day simple moving average is $0.53 and its 200-day simple moving average is $0.63. The stock has a market capitalization of $35.54 million, a P/E ratio of -0.99 and a beta of 1.48.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings results on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. The business had revenue of $5.39 million during the quarter, compared to analyst estimates of $3.93 million. As a group, analysts expect that BioLineRx will post -0.25 EPS for the current fiscal year.

Institutional Investors Weigh In On BioLineRx

Hedge funds have recently bought and sold shares of the company. Atria Investments Inc increased its position in BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after buying an additional 29,193 shares during the last quarter. PVG Asset Management Corp acquired a new position in shares of BioLineRx during the 2nd quarter worth approximately $70,000. Finally, CVI Holdings LLC bought a new stake in BioLineRx in the 2nd quarter valued at $462,000. 1.56% of the stock is currently owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.